

Q1 2021 RESULTS



“ Sanofi teams around the world have delivered another strong performance in the first quarter of 2021, powered by our growth drivers and the continued execution of our strategy. ”

PAUL HUDSON

CHIEF EXECUTIVE OFFICER, SANOFI

COMPANY SALES & BUSINESS EPS*

Q1 2021 COMPANY SALES*

€8,591M

+2.4% (-4.3%)

Q1 2021 BUSINESS EPS*

€1.61

+15% (+5.2%)

* Growth rates are expressed at constant exchange rates (CER).
Growth rates in parentheses are expressed on a reported basis.



€2,891M

Specialty Care



€915M

Vaccines



€3,672M

General Medicines



€1,113M

Consumer Healthcare

SALES BY GLOBAL BUSINESS UNIT

SALES BY GEOGRAPHY

US

€2,893M

EUROPE

€2,228M



REST OF THE WORLD

€3,470M

of which:

China **€726M**
Japan **€434M**
Brazil **€258M**
Russia **€151M**

NEW SOCIAL IMPACT STRATEGY



Strong commitment based on 4 pillars:

- Affordable access to medicines
- Support to vulnerable communities
- Preservation of the environment
- Inclusive work place



Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world's poorest countries access to 30 essential medicines

For further information on Q1 2021 results and definitions of financial indicators, please refer to the press release issued on April 28, 2021 at:

<https://www.sanofi.com/en/investors>



Sanofi.com



@Sanofi



Sanofi



@Sanofi

Sanofi.us



@SanofiUS



SanofiUS